2/6
08:30 am
gild
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
Low
Report
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
2/5
01:28 pm
gild
Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Low
Report
Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
2/4
03:07 pm
gild
GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]
Low
Report
GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]
2/2
07:41 pm
gild
Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]
Low
Report
Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]
2/1
12:59 pm
gild
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]
Low
Report
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]
1/31
03:52 pm
gild
Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results [Yahoo! Finance]
Low
Report
Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results [Yahoo! Finance]
1/31
12:53 pm
gild
UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook [Yahoo! Finance]
Low
Report
UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook [Yahoo! Finance]
1/31
09:20 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $114.00 to $146.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $114.00 to $146.00. They now have an "outperform" rating on the stock.
1/30
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.
1/29
09:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wolfe Research from $150.00 to $155.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wolfe Research from $150.00 to $155.00. They now have an "outperform" rating on the stock.
1/28
10:43 pm
gild
Gilead's Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story [Yahoo! Finance]
Low
Report
Gilead's Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story [Yahoo! Finance]
1/28
12:56 am
gild
U.S. names HIV, arthritis drugs for next Medicare price talks [CNBC]
Low
Report
U.S. names HIV, arthritis drugs for next Medicare price talks [CNBC]
1/27
05:32 pm
gild
Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial - Has The Bull Case Changed? [Yahoo! Finance]
1/27
04:05 pm
gild
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
Low
Report
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
1/27
10:59 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Truist Financial Corporation from $140.00 to $145.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Truist Financial Corporation from $140.00 to $145.00. They now have a "buy" rating on the stock.
1/27
09:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Citigroup Inc. from $140.00 to $156.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Citigroup Inc. from $140.00 to $156.00. They now have a "buy" rating on the stock.
1/26
01:22 pm
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at UBS Group AG from $145.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at UBS Group AG from $145.00 to $155.00. They now have a "buy" rating on the stock.
1/26
09:22 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at BMO Capital Markets from $135.00 to $150.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at BMO Capital Markets from $135.00 to $150.00. They now have an "outperform" rating on the stock.
1/24
12:30 am
gild
Gilead Sciences (NASDAQ:GILD) was downgraded by analysts at
Wall Street
Low
Report
Gilead Sciences (NASDAQ:GILD) was downgraded by analysts at
Wall Street
1/22
01:36 pm
gild
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer [Yahoo! Finance]
Low
Report
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer [Yahoo! Finance]
1/21
06:37 pm
gild
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer [Yahoo! Finance]
Low
Report
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer [Yahoo! Finance]
1/21
05:00 pm
gild
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Low
Report
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
1/21
04:27 pm
gild
BBH: Mature Biotech Exposure, But Limited Growth Ahead [Seeking Alpha]
Low
Report
BBH: Mature Biotech Exposure, But Limited Growth Ahead [Seeking Alpha]
1/21
09:21 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $153.00 to $159.00. They now have a "buy" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $153.00 to $159.00. They now have a "buy" rating on the stock.
1/20
09:24 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Royal Bank Of Canada from $100.00 to $103.00. They now have a "sector perform" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Royal Bank Of Canada from $100.00 to $103.00. They now have a "sector perform" rating on the stock.